IL17RB and breast cancer: Previously, it was shown that a simple homeobox B13:interleukin 17 receptor B two-gene ratio (hereafter referred to as HOXB13:IL17BR) could predict recurrence in a sample of patients with estrogen receptor (ER)-positive breast cancer receiving adjuvant tamoxifen therapy [1].